A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia - Daver, N; Vyas, P; Chao, M; Xing, G; Renard, C; Ramsingh, G; Sallman, DA; Wei, AH (Blood, 2021)